ONWARD Medical Reports First Quarter 2026 Results with Strong Commercial Momentum and Key Clinical Milestones

ONWARD Medical N.V., a neurotechnology company based in Eindhoven, Netherlands, announced its first-quarter 2026 results, highlighting commercial growth and clinical progress in spinal cord injury (SCI) therapies. The company supplied 70 ARC-EX external spinal cord stimulation systems, expanding access to over 100 clinics in the US and Europe, including home use for veterans. ARC-EX, the first FDA-cleared technology for improving hand strength and sensation in SCI patients, generated EUR 1.3 million in revenue for the quarter. In clinical milestones, ONWARD Medical initiated the Empower BP global pivotal study for its ARC-IM implantable system, with the first participant enrolled and implanted at Craig Hospital in Denver, Colorado. The study, involving 20 centers across the US, Canada, Europe, and the UK, aims to assess blood pressure management in SCI patients. Additionally, two individuals received investigational ARC-BCI therapy, combining brain-computer interfaces with spinal stimulation to restore limb movement. Financially, ONWARD Medical reported EUR 2.0 million in total revenue for Q1, with a EUR 53.4 million cash balance as of March 31. The company raised over EUR 40 million in equity capital in April, including a EUR 25 million investment from EQT Life Sciences, securing cash runway into Q1 2028. The funding was supported by demand from existing and new investors. The company’s ARC-IM platform also advanced in early-stage trials for Parkinson’s disease-related blood pressure instability, with one additional participant treated. ARC-BCI, the world’s first purpose-designed brain-spine interface system, continues to demonstrate potential for restoring movement in paralyzed limbs. CEO Dave Marver hosted a webcast on May 26 to discuss the results in further detail.